Majd Kobitary
Pulmonary Disease · Denver, CONPI 1649235748
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (52.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 78.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $6,168 and has fallen 86.8% since, to $814 in 2025.
Across 51 payments — averaging $280.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- Medical Device Business Services, Inc.$2K
- Pulmonx Corporation$1K
- Actelion Pharmaceuticals US, Inc.$123
- AstraZeneca$84
- Pinnacle Biologics, Inc$70
- plus $201 from 6 others
What the payments were for
- Travel & lodging$5,94842%
- Food & beverage$8346%
- Education$7,53153%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $11,209 |
| Medical Device Business Services, Inc. | 7 | $1,502 |
| Pulmonx Corporation | 9 | $1,124 |
| Actelion Pharmaceuticals US, Inc. | 2 | $123 |
| AstraZeneca | 4 | $84 |
| Pinnacle Biologics, Inc | 2 | $70 |
| GSK | 3 | $58 |
| Sanofi | 2 | $49 |
| Merck | 2 | $28 |
| Olympus Corporation Of The Americas | 1 | $26 |
| Insmed, Inc. | 1 | $21 |
| United Therapeutics Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,146
- ION$3,000
- MONARCH$1,382
- Pulmonx Endobronchial Valve EBV$1,011
- UPTRAVI$101
- OPSUMIT$101
How this compares
$14,313 in reported general payments places this provider in the 85th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $72,021 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $32,947 |
| Spiriva RespimatTiotropium Bromide | 20 | $23,179 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $19,367 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $16,705 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $2,790 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,684 |
| Montelukast Sodium | 57 | $474 |
| Prednisone | 41 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $58 | $121,673136 claims |
| AstraZenecaBreztri Aerosphere | $84 | $19,36730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Denver
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
- Barry MakeDenver$162K
- Amy OlsonDenver$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.